Berliner Boersenzeitung - Study shows how fast kilos return after ending weight-loss drugs

EUR -
AED 4.343054
AFN 77.464136
ALL 96.578481
AMD 443.001294
ANG 2.116924
AOA 1084.432259
ARS 1696.425045
AUD 1.722632
AWG 2.13043
AZN 2.015092
BAM 1.955364
BBD 2.363473
BDT 143.548016
BGN 1.986001
BHD 0.442401
BIF 3475.425631
BMD 1.182587
BND 1.500966
BOB 8.109193
BRL 6.256361
BSD 1.173439
BTN 107.717999
BWP 16.277373
BYN 3.32206
BYR 23178.695489
BZD 2.360074
CAD 1.622687
CDF 2578.039008
CHF 0.922409
CLF 0.026073
CLP 1029.489324
CNY 8.24689
CNH 8.21806
COP 4228.657801
CRC 580.770597
CUC 1.182587
CUP 31.338542
CVE 110.240437
CZK 24.267271
DJF 208.973438
DKK 7.466899
DOP 73.933527
DZD 153.154875
EGP 55.703589
ERN 17.738798
ETB 182.791072
FJD 2.661179
FKP 0.870315
GBP 0.866681
GEL 3.18162
GGP 0.870315
GHS 12.79115
GIP 0.870315
GMD 86.329235
GNF 10278.709772
GTQ 9.006993
GYD 245.515296
HKD 9.221278
HNL 30.954103
HRK 7.533317
HTG 153.905708
HUF 382.153287
IDR 19840.785951
ILS 3.707232
IMP 0.870315
INR 108.316693
IQD 1537.357457
IRR 49816.456691
ISK 145.777895
JEP 0.870315
JMD 184.718842
JOD 0.838501
JPY 184.146504
KES 151.256298
KGS 103.416722
KHR 4722.947667
KMF 496.686746
KPW 1064.353704
KRW 1710.387141
KWD 0.362349
KYD 0.977982
KZT 590.738376
LAK 25359.349612
LBP 105085.885516
LKR 363.548997
LRD 217.091629
LSL 18.94048
LTL 3.491871
LVL 0.715335
LYD 7.466336
MAD 10.748905
MDL 19.97255
MGA 5308.817127
MKD 61.616271
MMK 2483.187819
MNT 4218.830116
MOP 9.4253
MRU 46.916546
MUR 54.292994
MVR 18.271409
MWK 2034.84661
MXN 20.533372
MYR 4.736855
MZN 75.57955
NAD 18.94048
NGN 1680.526824
NIO 43.180379
NOK 11.555294
NPR 172.348599
NZD 1.987207
OMR 0.454249
PAB 1.173539
PEN 3.936823
PGK 5.018882
PHP 69.733624
PKR 328.342141
PLN 4.208885
PYG 7847.251532
QAR 4.278347
RON 5.101724
RSD 117.373848
RUB 89.207823
RWF 1711.518652
SAR 4.433442
SBD 9.606873
SCR 16.856244
SDG 711.330129
SEK 10.584272
SGD 1.505082
SHP 0.887246
SLE 28.859447
SLL 24798.24684
SOS 669.450838
SRD 45.081425
STD 24477.153012
STN 24.494542
SVC 10.267712
SYP 13078.904017
SZL 18.935781
THB 36.920787
TJS 10.972155
TMT 4.139053
TND 3.416239
TOP 2.847384
TRY 51.246799
TTD 7.971224
TWD 37.116428
TZS 3004.130641
UAH 50.599026
UGX 4148.075755
USD 1.182587
UYU 44.440098
UZS 14242.826515
VES 416.584326
VND 31036.982812
VUV 141.661813
WST 3.258757
XAF 655.810877
XAG 0.011483
XAU 0.000237
XCD 3.196
XCG 2.114929
XDR 0.815618
XOF 655.810877
XPF 119.331742
YER 281.814608
ZAR 19.0597
ZMK 10644.701884
ZMW 23.02187
ZWL 380.792372
  • SCS

    0.0200

    16.14

    +0.12%

  • RBGPF

    -0.8100

    83.23

    -0.97%

  • NGG

    1.3200

    81.5

    +1.62%

  • VOD

    0.2300

    14.17

    +1.62%

  • RELX

    0.0600

    39.9

    +0.15%

  • CMSC

    0.1000

    23.75

    +0.42%

  • GSK

    0.5000

    49.15

    +1.02%

  • BCE

    0.4900

    25.2

    +1.94%

  • RYCEF

    0.3000

    17.12

    +1.75%

  • BTI

    0.9400

    59.16

    +1.59%

  • RIO

    3.1300

    90.43

    +3.46%

  • BP

    1.1000

    36.53

    +3.01%

  • JRI

    0.0100

    13.68

    +0.07%

  • CMSD

    0.0900

    24.13

    +0.37%

  • BCC

    -1.1800

    84.33

    -1.4%

  • AZN

    1.2600

    92.95

    +1.36%

Study shows how fast kilos return after ending weight-loss drugs
Study shows how fast kilos return after ending weight-loss drugs / Photo: Armend NIMANI - AFP/File

Study shows how fast kilos return after ending weight-loss drugs

When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.

Text size:

But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.

A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.

They have been found to help people lose between 15-20 percent of their body weight.

"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.

However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.

This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.

So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.

Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.

While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.

However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.

The researchers projected that the participants would return to their original weight in 18 months.

Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.

People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.

This meant that people taking the drugs regained their weight four times faster.

- 'Starting point, not a cure' -

"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.

But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.

This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.

Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."

"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.

If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.

"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.

"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.

(G.Gruner--BBZ)